[HTML][HTML] PRISMA—efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials
MC Wang, LY Zhang, W Han, Y Shao, M Chen, R Ni… - Medicine, 2014 - journals.lww.com
PRISMA—Efficacy and Safety of Vedolizumab for Inflammatory B... : Medicine PRISMA—Efficacy
and Safety of Vedolizumab for Inflammatory Bowel Diseases: A Systematic Review and …
and Safety of Vedolizumab for Inflammatory Bowel Diseases: A Systematic Review and …
PRISMA--efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials
MC Wang, LY Zhang, W Han, Y Shao, M Chen… - …, 2014 - pubmed.ncbi.nlm.nih.gov
Vedolizumab is an anti-inflammatory monoclonal antibody that exclusively targets the α4β7
integrin. We aimed to systematically review the efficacy and safety of vedolizumab for …
integrin. We aimed to systematically review the efficacy and safety of vedolizumab for …
[HTML][HTML] PRISMA—Efficacy and Safety of Vedolizumab for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
MC Wang, LY Zhang, W Han, Y Shao, M Chen, R Ni… - Medicine, 2014 - ncbi.nlm.nih.gov
PRISMA—Efficacy and Safety of Vedolizumab for Inflammatory Bowel Diseases - PMC Back
to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …
to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …
[PDF][PDF] PRISMA—Efficacy and Safety of Vedolizumab for Inflammatory Bowel Diseases
MC Wang, LY Zhang, W Han, Y Shao, M Chen, R Ni… - Medicine, 2014 - researchgate.net
PRISMA—Efficacy and Safety of Vedolizumab for Inflammatory Bowel Diseases Page 1
PRISMA—Efficacy and Safety of Vedolizumab for Inflammatory Bowel Diseases A Systematic …
PRISMA—Efficacy and Safety of Vedolizumab for Inflammatory Bowel Diseases A Systematic …
PRISMA-Efficacy and Safety of Vedolizumab for Inflammatory Bowel Diseases A Systematic Review and Meta-Analysis of Randomized Controlled Trials
MC Wang, LY Zhang, W Han, Y Shao, M Chen, R Ni… - 2014 - ir.lzu.edu.cn
摘要Vedolizumab is an anti-inflammatory monoclonal antibody that exclusively targets the
alpha 4 beta 7 integrin. We aimed to systematically review the efficacy and safety of …
alpha 4 beta 7 integrin. We aimed to systematically review the efficacy and safety of …
PRISMA--efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials.
MC Wang, LY Zhang, W Han, Y Shao, M Chen, R Ni… - Medicine, 2014 - europepmc.org
PRISMA--efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review
and meta-analysis of randomized controlled trials. - Abstract - Europe PMC Sign in | Create an …
and meta-analysis of randomized controlled trials. - Abstract - Europe PMC Sign in | Create an …
[PDF][PDF] PRISMA—Efficacy and Safety of Vedolizumab for Inflammatory Bowel Diseases
MC Wang, LY Zhang, W Han, Y Shao, M Chen, R Ni… - Medicine, 2014 - cyberleninka.org
PRISMA—Efficacy and Safety of Vedolizumab for Inflammatory Bowel Diseases Page 1
PRISMA—Efficacy and Safety of Vedolizumab for Inflammatory Bowel Diseases A Systematic …
PRISMA—Efficacy and Safety of Vedolizumab for Inflammatory Bowel Diseases A Systematic …
PRISMA--efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials.
MC Wang, LY Zhang, W Han, Y Shao, M Chen, R Ni… - Medicine, 2014 - europepmc.org
PRISMA--efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review
and meta-analysis of randomized controlled trials. - Abstract - Europe PMC Sign in | Create an …
and meta-analysis of randomized controlled trials. - Abstract - Europe PMC Sign in | Create an …